All In Biotech

Drug Trial Radar · NCT06255223

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Multimodal Radiotherapy in the Treatment of Renal Cell Carcinoma Progressed After Prior Immunotherapy

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Dec 15, 2023

Primary completion

Dec 1, 2027

Study completion Dec 1, 2029

Sponsor

Lead sponsor
Jinling Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.

Conditions

  • Renal Cell Carcinoma
  • Radiotherapy
  • Immune Checkpoint Inhibitor

Interventions

  • High-dose Radiotherapy (HDRT)Radiation

    SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).

  • Low-dose Radiotherapy (LDRT)Radiation

    Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.

  • Anti-PD-1 monoclonal antibodyDrug

    At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease control rate (DCR)Time frame: Up to 1 year
  2. Incidence of adverse eventsTime frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.